- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01897207
Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer
August 14, 2015 updated by: Prof. Dr. Silke Gillessen, Cantonal Hospital of St. Gallen
The main aim of this trial is to assess the response rate, the feasibility and toxicity of the treatment with antigen loaded Dendritic Cell Vaccination in Prostate Cancer patients.
Furthermore we want to investigate biological responses by measuring markers of in-vivo and ex-vivo immunomodulation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Dendritic cell (DC)-based immunotherapy is a promising approach to augment tumor antigen-specific T cell responses in cancer patients.
However, tumor escape with down-regulation or complete loss of target antigens may limit the susceptibility of tumor cells to the immune attack.
Concomitant generation of T cell responses against several immunodominant antigens may circumvent this potential drawback.
In this phase I/II clinical trial, the investigators determined the immunostimulatory capacity of autologous DC pulsed with multiple T cell epitopes derived from four different prostate-specific antigens in patients with advanced hormone-refractory prostate cancer.
Autologous DC of HLA-A*0201-positive patients are loaded with antigenic peptides derived from prostate stem cell antigen, prostatic acid phosphatase, prostate-specific membrane antigen, and prostate-specific antigen.
A strict quality control concerning the expression of surface markers and the migratory capacity of the DC secured optimal stimulatory capacity.
DC were applied intradermally six times at biweekly intervals followed by monthly booster injections.
Tolerability and PSA response will be investigated.
Antigen-specific immune responses will be quantified.
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- histologically or cytologically proven prostatic carcinoma
- proven hormonal resistance: tumor progression after orchiectomy or during treatment with hormonal agents. Patients treated with antiandrogens, such as flutamide (Flucinom) or bicalutamide (Casodex), should have been discontinued the drug 6 weeks prior to the trial entry followed by no tumor response within this 6 weeks
- not amenable to curative therapy
- patients with measurable and non-measurable disease may be included. Bone lesions only are considered to be non-measurable
- two consecutive increases of prostate-specific antigen (PSA) should be documented over a previous reference value (N°1). The first increase in PSA (N°2) should occur a minimum of one week from the reference value and be confirmed (N°3). If this value is less than the previous value, the patient is still eligible if the next PSA(N°4) is found to be higher than the second PSA. Serum levels of prostate-specific antigen must be at least 10 microg/l
- Previous radiotherapy is allowed if it has been stopped 4 weeks or more before the trial treatment and did not involve lesions used to evaluate activity of the trial drugs
- one previous chemotherapy (including Estracyt) is allowed, but the chemotherapy should have been stopped at least 6 weeks before study entry
- age >18 years
- performance status 0,1,2 (ECOG, Appendix I)
- no concurrent therapy with steroids
- no uncontrolled infections
- live expectancy more than 3 months
- Human leukocyte antigen (HLA)-Type has to be HLA*A201
- neutrophile count >1500/microl and thrombocytes >100 000/microl
- creatinine <1.5 of upper normal level
- adequate liver function with bilirubin <2 of upper normal level, alanine aminotransferase (ALAT) and aspartate transamionase (ASAT) < 3 x upper normal level
- absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- before patient registration/randomization, informed consent must be given according to good clinical practice (GCP), and national/local regulations
Exclusion Criteria:
- serious concomitant disease (cardiac, pulmonary and others)
- brain metastasis
- previous splenectomy or radiotherapy to the spleen
- concurrent therapy with immunosuppressive drugs
- chronic immunosuppression (includes transplantation or HIV-infection) HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) (test required) or any other severe uncontrolled infection other neoplastic diseases except: curatively treated basal cell or squamous cell carcinoma of the skin or relapse free for more than 5 years after curative treatment of a neoplasm
- treatment with other investigational drugs during the last month
- severe autoimmune disease
- chemotherapy, radiotherapy or immunotherapy less than 6 weeks before study entry
- Ejection fraction (measured by echocardiography) < 40%
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Dendritic cell application
|
S.C. injection of peptide pulsed autologous dendritic cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
tolerability and toxicity and feasibility of this regimen
Time Frame: directly after vaccination (within 24 h)
|
directly after vaccination (within 24 h)
|
|
response rate or PSA response in non measurable disease
Time Frame: Change from baseline in serum PSA at 6, 10 and 12 weeks
|
The given time frame reflects the minimum of PSA values.
From Patients receiving more than 6 DC vaccination every 4 weeks PSA was determined until the end of DC vaccination (longest was one and a half year).
|
Change from baseline in serum PSA at 6, 10 and 12 weeks
|
ex-vivo immunomodulation
Time Frame: before vaccination, after 6, 10, 12, and up to 85 weeks
|
Peripheral blood mononuclear cells (PBMC) isolation and in-vitro restimulation.
Measurement of antigen specific immune responses.
|
before vaccination, after 6, 10, 12, and up to 85 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pain relief
Time Frame: Change from baseline in pain relief at 2, 4, 6, 8, 10 and 12 weeks
|
Changes in pain intensity will be assessed by summarizing score items 9 and 19 of the European Organisation for Research and Treatment of Cancer (EORTC)quality of life questionnaire (QLQ-C30) quality.
Additionally, analgesic consumption will be rated by a pain treatment score (PTS).
|
Change from baseline in pain relief at 2, 4, 6, 8, 10 and 12 weeks
|
Overall survival
Time Frame: From first date of treatment until dead
|
From first date of treatment until dead
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Thomas Cerny, Prof. Dr., Department of Medical Oncology, Cantonal Hospital St. Gallen, Switzerland
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2002
Primary Completion (ACTUAL)
August 1, 2009
Study Completion (ACTUAL)
October 1, 2011
Study Registration Dates
First Submitted
June 26, 2013
First Submitted That Met QC Criteria
July 9, 2013
First Posted (ESTIMATE)
July 11, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
August 17, 2015
Last Update Submitted That Met QC Criteria
August 14, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SG226_02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer of the Prostate
-
Dana-Farber Cancer InstituteCompletedProstate Cancer | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
Guy's and St Thomas' NHS Foundation TrustActive, not recruiting
-
Assistance Publique - Hôpitaux de ParisUnknownCancer of the PROSTATEFrance
-
University of Michigan Rogel Cancer CenterCompleted
-
Alliance Foundation Trials, LLC.Patient-Centered Outcomes Research InstituteCompletedProstate Cancer | Cancer of the Prostate | Prostatic Cancer | Cancer of Prostate
-
Astellas Pharma IncAstellas Pharma US, Inc.CompletedProstate Cancer | Cancer of the Prostate | Prostatic Cancer | Cancer of ProstateNetherlands, United States, United Kingdom
-
DendreonCompletedProstate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of ProstateAustria, France, Netherlands, United Kingdom
-
UNC Lineberger Comprehensive Cancer CenterPatient-Centered Outcomes Research InstituteCompletedProstate Cancer | Cancer of the Prostate | Prostatic Cancer | Cancer of ProstateUnited States
-
Roswell Park Cancer InstituteUniversity of PittsburghCompletedProstate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of ProstateUnited States
-
Case Comprehensive Cancer CenterTerminatedAdenocarcinoma of Prostate | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
Clinical Trials on Dendritic cell application
-
Prof. Dr. Silke GillessenTerminated
-
Hospital Clinic of BarcelonaCompleted
-
Zhujiang HospitalSun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Shenzhen Geno-Immune...RecruitingMyelodysplastic Syndromes | Leukemia, Acute Myelogenous (AML) | Leukemia, Acute Lymphocytic (ALL)China
-
Universitair Ziekenhuis BrusselRIZIVCompletedMalignant Melanoma Stage III | Malignant Melanoma Stage IVBelgium
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Immunex CorporationWithdrawnAcute Myelogenous Leukemia | Chronic Myelogenous Leukemia
-
Beth Israel Deaconess Medical CenterMassachusetts General Hospital; Rambam Health Care Campus; Dana-Farber Cancer... and other collaboratorsCompletedMultiple MyelomaUnited States, Israel
-
University Hospital, AntwerpCompletedRenal Cell Carcinoma | Glioblastoma | Malignant Mesothelioma | Colorectal Tumors | Breast Cancers | SarcomasBelgium
-
Rockefeller UniversityMemorial Sloan Kettering Cancer CenterCompleted
-
Argos TherapeuticsCompletedRenal Cell CarcinomaCanada, United States
-
Jan WalewskiCompletedLymphoma | Multiple Myeloma and Plasma Cell NeoplasmPoland